Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for AGALSIDASE BETA
- Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
- Switch Over Study of Biosimilar AGA for Fabry Disease
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
- China Post-marketing Surveillance (PMS) Study of Fabrazyme®
- To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
- Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease
- Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
- Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
- Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease
- Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) Study
- The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study
- An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
- A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.
- A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease
- Replagal Enzyme Replacement Therapy for Children With Fabry Disease
- Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
- Dosing Study of Replagal in Patients With Fabry Disease
Clinical trials list
click for details